• FindA University Ltd Featured PhD Programmes
  • University of Cambridge Featured PhD Programmes
  • Aberdeen University Featured PhD Programmes
  • Staffordshire University Featured PhD Programmes
  • University of Tasmania Featured PhD Programmes
  • University of Pennsylvania Featured PhD Programmes
University of Liverpool Featured PhD Programmes
Peter MacCallum Cancer Centre Featured PhD Programmes
Imperial College London Featured PhD Programmes
Coventry University Featured PhD Programmes
University of Tasmania Featured PhD Programmes

Molecular pathology of drug resistance in chronic myeloid leukaemia.

This project is no longer listed in the FindAPhD
database and may not be available.

Click here to search the FindAPhD database
for PhD studentship opportunities
  • Full or part time
    Dr Laslo
  • Application Deadline
    Applications accepted all year round
  • Self-Funded PhD Students Only
    Self-Funded PhD Students Only

Project Description

Chronic Myeloid Leukaemia (CML) represents 15% of all adult leukaemias and is associated with the t(9:22) chromosome translocation which fuses the BCR and ABL1 genes. The oncogene product, BCR-ABL, is the driving mutation of CML and its constitutive tyrosine kinase activity is central for its pathology. Targeting the tyrosine kinase activity of BCR-ABL for therapeutic application was first suggested in 1992 and these findings spawned the generation of Imatinib Mesylate (IM) 4-years later. The clinical success in treating CML with IM is a major success in targeted molecular therapy.

However, in some patients the disease turns aggressive and patients rapidly become resistant to current drug therapies. Development of resistance to drug therapies represents a significant hindrance to the effective treatment of cancer patients. Currently there is no effective non-surgical option for these patients with fatality occurring within 12-months.

Development of drug resistant BC-CML remains a clinical challenge and there is an urgent need to develop novel therapies for this pathology. The most widely studied mechanism by which leukaemic cells acquire IM-resistance is acquisition of point mutations within the tyrosine kinase domain of BCR-ABL. However, such mutations account for ~40% of patients, with a majority of drug resistant patients harbouring a wild-type BCR-ABL allele.

These clinical observations demonstrate that CML can become BCR-ABL kinase independent. Yet, how do leukaemic cells continue to survive and grow in the absence of BCR-ABL kinase activity?

To understand how CML cells have learnt to be kinase independent our lab has established a pre-clinical model that phenocopies this transition. Specifically, these drug-resistant derivatives recapitulate the clinical observations in that the activity of BCR-ABL is significantly diminished in the presence of IM yet the cells continue to grow and survive unperturbed.

This model system is a powerful model to gain insight into the molecular basis of this disease and can be used as platforms for drug screens.

The PhD project will employ a systems-biology approach (genome wide expression analysis, bio-informatics and shRNA technology) with the specific aims to (i) identify regulatory factors whose expression is dysregulated as a direct consequence of acquisition of drug resistance and (ii) attempt to rescue the developmental block by restoring the functional activity of these dsyregulated genes.

The PhD student will gain experience in a broad range of molecular and cell biology techniques including standard recombinant DNA procedures, gene expression profiling, micro-array analysis, bio-informatics, shRNA and general tissue culture practice with culturing of both primary and established cell lines.

Informal enquiries to Dr. Peter Laslo, email: [email protected]

http://medhealth.leeds.ac.uk/info/940/experimental_haematology/398/myeloid_differentiation

The Section of Experimental Haematology is a vigorous and highly interactive department. The Section consists of faculty members studying the molecular regulation of cell fate specification and differentiation during blood cell development. This is complimented by studies on the dysregulation of haematopoiesis in cancers (leukemias and lymphomas).

You will join the Leeds Institute of Cancer and Pathology, a world-class multi-disciplinary research institute, dedicated to defining the molecules involved in human diseases. Further details of the Institute’s research:
http://medhealth.leeds.ac.uk/info/900/leeds_institute_of_cancer_and_pathology

Funding Notes

This project is available immediately to self-funded applicants with government scholarships or other sources. Self-funded students must be able to provide oversees rate University Tuition Fees (see UoL Website) plus a minimum of £12,000 laboratory consumables costs per year. This is in addition to the provision of personal living expenses.

Applicants with sufficient funding must still undergo formal interview prior to acceptance in order to demonstrate scientific aptitude and English language capability.

Applications can be made throughout the year.

Share this page:

Cookie Policy    X